Y-mAbs Therapeutics, Inc.: accounts_receivable
| Value | {"amount": 20588000, "concept": "us-gaap:AccountsReceivableNetCurrent", "currency": "USD"} |
|---|---|
| Period | (as of 2024-03-31) |
| Status | current |
| Entity | Y-mAbs Therapeutics, Inc. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T17:37:23.958445+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/13cc17b6-9592-4872-b713-2896630b0c3e
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001558370-24-007056Retrieved: 2026-08-19T17:37:23.958445+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001722964/accounts-receivable/2024-03-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/13cc17b6-9592-4872-b713-2896630b0c3e
History
- no predecessors — first report